Stilla Technologies develops and provides digital PCR solutions and technologies for genetic analysis in life sciences research and molecular diagnostics.

Stilla Technologies

Stilla- About us

Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla’s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world's first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics. Visit the website and connect on Twitter @StillaTech

Kurma Partners

Illumina Ventures

BNP Paribas Développement

Casdin Capital

Eurazeo

LBO France

Tusholdings

European Investment Bank

Idinvest Partners

Paris-Saclay Seed Fund

Zhongyuan Yuzi Investment Group

CLIFF

Breakthroughs in Oncology: Digital PCR Leading the Change

Join us at TranslaTUM in Munich for an insightful seminar on “Digital PCR and its Applications in Cancer Research,” hosted by Stilla Technologies.
This seminar will explore how digital PCR is revolutionizing cancer detection, monitoring, and treatment.

Featured Speakers:

- Dr. Simon Stilling, Stilla Technologies
- Dr. Marius Pollet, actome

Why Attend?

Gain expert insights 🧠💡
Discover innovative applications 🔍✨
Network with professionals in the field 🤝👥

📅 September 4th, 2024
📍 Munich

Limited spots available—register now for free!

#CancerResearch #DigitalPCR #Oncology #StillaTechnologies #munich #seminar

✨Highlights from Last Week with Stilla Technologies!✨
 
Last week, Stilla Technologies participated in a series of exciting seminars and live demos at centers of excellence with CARLO ERBA Reagents (DASIT Group). We delved into the fundamentals of Digital PCR and the ultra-sensitive detection of high-plex cancer mutations using Crystal Digital PCR® and Nio™+. 

Our "all-in-one" platforms, featuring 🌈7 colors and the automation-ready Nio™ , were the stars of the show! 🌟
 
Want to learn more about Nio™ Digital PCR too? Book your demo meeting now with the Stilla Team.

Check the link in the first comment 👇 .

We're excited to announce our distribution relationship with Avantor, making our products for digital PCR more readily accessible to customers across the USA. 

At the same time, we announce the expansion of our content offerings with a focus on Cell and Gene Therapy, biopharma quality control, infectious diseases, and applied testing. 

You can read the full announcement below.

#biopharma #genetherapy #digitalPCR #stilla

The Nio family is expanding!
 
We’re introducing two new digital PCR system configurations for Nio™: the entry-level Nio™ E, for essential, and the mid-level Nio™. These new additions complement our flagship Nio™+, launched in November 2023.
 
All instruments in the Nio™ family share cutting-edge capabilities: 
🔬 an "all-in-one" design for a fully integrated digital PCR workflow
🌈 7-color detection for unparalleled multiplexing
🤖 Automation readiness with a standard SBS plate format
 
Each Nio™ configuration provides tailored throughput options:
Nio™ E: 48 samples per run
Nio™: 192 samples per run with continuous loading
Nio™+: 384 samples per run with continuous loading
 
Reach out through our website for more information.

#digitalPCR #stillatechnologies

Advancing Your Research with Custom Digital #PCR Assays. 

Discover with Stilla® the benefits of customized assays tailored to meet your lab needs:

🔍 Tailored Solutions: Start with your target sequence, and we’ll provide solutions that align with your project goals.

⏱️ Unparalleled Speed: Enjoy rapid design and delivery using Crystal Flex Probe technology for quick customization and optimization.

💡 Highest Multiplexing: Detect and quantify up to 21 targets in a single reaction – an unmatched level of multiplexing in dPCR.

Crystal Flex Probes are designed to make your multiplexing experience easy.

Learn more about our streamlined assay customization process and get started today  👇
#Stillatechnologies #Lifesciences #Laboptimization #dPCR

Our groundbreaking Nio™️+ has been featured in Bref Eco! 🌟

Developed in Roanne, Nio™️+ is revolutionizing digital PCR with unparalleled precision in diagnostics, setting a new industry standard.

Our Nio™️+ journey is a proud testament to French innovation, combining the excellence of La French Tech and La French Fab.

📖 For an in-depth look, read Alban Razia’s insightful article in the special open-access issue of Bref Eco.

👉 Discover more about Nio™️+: 
https://lnkd.in/e-MUtxqU

👉 Stay updated by subscribing to Bref Eco: https://lnkd.in/evfS_dKx 

👉 Read the special issue: 
https://lnkd.in/eN52rqrY

#DigitalPCR #industriedufutur #biotech #iso13485 #iso62304 #medtech 
#healthtech #MedicalDevice

news impact assignment basic	general
public peers	general	Aug 26, 2024 11:40 AM	ba94e789
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 26, 2024 11:40 AM	b1a494e8
translate crunchbase fundingrounds	general
peers	general	Aug 26, 2024 11:40 AM	4c1b492b
news basic	general	Aug 26, 2024 11:40 AM	aa2388e9
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

STIL

COM:STILLATECHNOLOGIES

Stilla Technologies